A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).

TPS5088Background: Despite recent treatment advances, mCRPC remains a challenging disease associated with significant mortality and morbidity. Prostate specific membrane antigen (PSMA) is a transme...